[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Florence\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":375},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,49,75,101,126,148,167,190,226,255,282,311,342],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100547581","rimegepant-effectiveness-and-tolerability-as-migraine-preventive-treatment-100547581",false,"NCT06409832","RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment","RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment: a Prospective, Multicentric, Cohort Study (RAISE)","RAISE","Inclusion Criteria:\n\n* Diagnosis of migraine without aura or migraine with aura, according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);\n* At least 4 monthly migraine days;\n* Good compliance to study procedures;\n* Availability of headache diary at least of the preceding months before enrollment.\n\nExclusion Criteria:\n\n* Subjects with contraindications for use of gepants;\n* Diagnosis of chronic migraine\n* Concomitant diagnosis of medical diseases and\u002For comorbidities that, in the Investigator's opinion might interfere with study assessments;\n* medical comorbidities that could interfere with study results;\n* Pregnancy and breastfeeding.\n* Changes in preventive treatments in the month before the first administration of rimegepant","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","2 Years","OBSERVATIONAL","The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.",[26,27,28],"Migraine","Migraine With Aura","Migraine Without Aura",[30,31,32,33,34,35],"Headache","Medication overuse headache","Pain","Migraine prevention","Gepant","Rimegepant","RECRUITING","2026-06-09",{"date":39,"type":40},"2026-06-11","ACTUAL",{"date":42,"type":40},"2024-03-26",{"date":44,"type":21},"2027-09",{"name":46,"class":47},"University of Florence","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100643694","study-of-peripheral-neuropathy-in-patients-with-advanced-urothelial-cancer-treated-with-enfortumab-vedotin-and-pembrolizumab-with-supportive-neuridase-endeavor-100643694","NCT07629700","Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR)","ENDEAVOR Study: A Prospective Exploratory Study Describing the Course of Peripheral Neuropathy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin in Combination With Pembrolizumab and Supportive Neuridase","ENDEAVOR","IInclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed locally advanced or metastatic urothelial carcinoma\n* Candidate for treatment with enfortumab vedotin in combination with pembrolizumab according to clinical practice\n* Ability to provide written informed consent\n* Adequate clinical conditions to participate in the study according to investigator judgment\n\nExclusion Criteria:\n\n* Pre-existing severe peripheral neuropathy that may interfere with study assessments\n* Contraindications to enfortumab vedotin or pembrolizumab according to clinical practice\n* Known hypersensitivity to components of Neuridase\n* Pregnancy or breastfeeding\n* Any medical, psychiatric, or social condition that, in the investigator's judgment, may interfere with study participation or interpretation of results",{"count":58,"type":21},40,"INTERVENTIONAL",[61],"NA","his prospective exploratory study aims to describe the course of peripheral neuropathy in patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin in combination with pembrolizumab and receiving supportive Neuridase.\n\nPeripheral neuropathy is a common adverse event associated with enfortumab vedotin and may negatively affect treatment tolerability, quality of life, and treatment continuation. Neuridase is a non-pharmacological supportive product intended to support peripheral nervous system function; however, its role in this clinical setting has not yet been established.\n\nParticipants enrolled in this single-arm study will receive standard-of-care treatment with enfortumab vedotin plus pembrolizumab, together with supportive Neuridase according to clinical practice. The study will prospectively assess neuropathy symptoms and severity using clinical evaluations and patient-reported outcome measures, including quality-of-life questionnaires, over the course of treatment.\n\nThe objective of the study is to explore neuropathy patterns and treatment tolerability in this patient population.",[64,65],"Urothelial Carcinoma (UC)","Peripheral Nerve Disease","NOT_YET_RECRUITING","2026-06-04",{"date":69,"type":40},"2026-06-08",{"date":71,"type":21},"2026-09-01",{"date":73,"type":21},"2028-09-01",{"name":46,"class":47},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":59,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100526516","psychosomatic-intervention-in-fibromyalgia-100526516","NCT06135753","Psychosomatic Intervention in Fibromyalgia.","Psychosomatic Assessment and Intervention in Fibromyalgia","PSY-FM","Inclusion Criteria:\n\n1. able and interested in participating to the research, as proved by signed Informed consent;\n2. a diagnosis of FM according to the Italian Society for Rheumatology clinical practice guidelines (Ariani et al., 2021)\n3. age higher than 18 years\n\nExclusion Criteria:\n\n1. co-occurrence of psychiatric disorder(s) according to the Diagnostic and Statistical Manual of mental disorders, 5th edition (American Psychiatric Association, 2013) as diagnosed via the Mini-International Neuropsychiatric Interview;\n2. currently under psychotherapy;\n3. pharmacological modifications during the period of the trial;\n4. undergoing non pharmacological interventions during the period of the trial",{"count":20,"type":21},[61],"Fibromyalgia is a widespread musculoskeletal pain syndrome. It is characterized by physical manifestations which are also the expression of a psychological distress as well as specific illness attitudes and behaviors. Indeed, it is considered a psychosomatic disorder. In this framework, we hypothesize the clinical utility of a psychosomatic assessment guided by rheumatologists and clinical psychologists (Study 1) and the utility of an integrated multidisciplinary psychosomatic intervention based on cognitive restructuring\u002Fpsychoeducation followed by museum therapy (Study 2). For Study 1 a cross-sectional observation study will be implemented, for Study 2 a randomized controlled trial will be applied.",[87],"Fibromyalgia",[87,89,90,91],"Psychosomatic Intervention","Cognitive Restructuring","Museum Therapy","2026-04-29",{"date":94,"type":40},"2026-05-05",{"date":96,"type":40},"2023-11-01",{"date":98,"type":21},"2026-12-30",{"name":46,"class":47},1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":59,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":48},"100316803","study-on-30-outpatients-with-chronic-migraine-treated-with-well-being-therapy-or-with-a-control-therapy-100316803","NCT03404336","Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy","Pilot Randomized Controlled Trial to Evaluate the Efficacy of Well-Being Therapy vs a Control Condition in Chronic Migraine Patients","Inclusion criteria:\n\n1. able and interested in participating to the present research project, as proved by signed Informed consent;\n2. 18-65 years of age;\n3. Italian mother tongue;\n4. diagnosis of chronic migraine according to the International Classification of Headache Disorders. Thus, presenting specific features (i.e., unilateral and pulsating pain of moderate or severe intensity, which is aggravated or precipitated by routine physical activities and is combined with nausea and\u002For vomiting, photophobia, and phonophobia) and migraine headache on ≥ 15 days per month;\n5. headache chronicity for a minimum of 1 year and pattern of headache symptoms stable for a period of at least 6 months;\n6. no pharmacological therapy or dietary supplements use for chronic migraine OR pharmacological therapy\u002Fdietary supplement use for chronic migraine stable since at least 3 months;\n7. psychotropic medication allowed only if stable since at least three months.\n\nExclusion criteria:\n\n1. diagnosis of medication overuse headache;\n2. co-occurrence of psychiatric disorder(s) according to the Diagnostic and Statistical Manual of mental disorders (DSM) 5th edition as diagnosed via the MINI International Neuropsychiatric Interview;\n3. co-occurrence of chronic unstable medical conditions;\n4. being pregnant or lactating;\n5. under exogeneous hormones treatment (i.e., hormonal contraceptives, postmenopausal hormone therapy);\n6. any other condition that, according to the Investigators' opinion, may alter the ability of the patient to follow study procedures.","65 Years",{"count":110,"type":21},30,[61],"Chronic migraine is a disabling type of migraine and is often resistant to treatment. Non-pharmacological interventions have been investigated as potential treatment although, unfortunately, the literature on their efficacy is poor and showed mixed results. Well-Being Therapy (WBT) is a brief psychotherapy which has shown efficacy in decreasing the relapse rates of depression in adults, in generalized anxiety disorder and in cyclothymia. It can be implemented to empower psychological well-being. The aim of the present study is to test the efficacy of WBT in a sample of patients with chronic migraine to verify if it reduces the disability due to migraine and distress, it increases the psychological well-being as well as the level of euthymia.",[114],"Chronic Migraine",[116,117,118,119,120],"migraine","chronic","well-being therapy","psychotherapy","therapy",{"date":94,"type":40},{"date":123,"type":40},"2018-10-01",{"date":98,"type":21},{"name":46,"class":47},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":100},"100564418","the-effectiveness-of-eptinezumab-during-a-migraine-attack-the-be-free-study-100564418","NCT06628921","The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)","BEFREE","Inclusion Criteria:\n\n* Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the third edition of the ICHD (ICHD-III).\n* At least 8 days of migraine per month.\n* Adequate compliance with study procedures.\n* Availability of a migraine diary for at least one month prior to enrollment.\n* Ongoing attack before administration.\n* Included in the TACHIS study (NCT06409845)\n\nExclusion Criteria:\n\n* Subjects with contraindications to the use of eptinezumab.\n* Concomitant diagnosis of medical conditions and\u002For comorbidities that, in the investigator's opinion, could interfere with the study's assessments and outcomes.\n* Pregnancy and breastfeeding.\n* Changes in concomitant preventive therapy in the month prior to the initiation of eptinezumab.",{"count":134,"type":21},50,"A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved.\n\nThe study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe\\_5)",[26],[138,32,116,139],"headache","Eptinezumab","2026-01-19",{"date":142,"type":40},"2026-01-21",{"date":144,"type":40},"2024-10-30",{"date":146,"type":21},"2026-10-30",{"name":46,"class":47},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":48},"100508638","gepant-treatments-effectiveness-and-tolerability-gainer-100508638","NCT05903027","Gepant treAtments: EffectIveNess and tolERability (GAINER)","Effectiveness and Tolerability of Rimegepant as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study (GAINER)","GAINER","Inclusion Criteria:\n\n* Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III).\n* At least 3 MMDs\n* Good compliance to study procedures\n* Availability of headache diary at least of the preceding months before enrollment\n\nExclusion Criteria:\n\n* Subjects with contraindications for use of gepants;\n* Concomitant diagnosis of medical diseases and\u002For comorbidities that, in the Investigator's opinion might interfere with study assessments;\n* medical comorbidities that could interfere with study results;\n* Pregnancy and breastfeeding.",{"count":20,"type":21},"The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.",[26,27,28,114],[30,31,32,34,160],"Triptan",{"date":142,"type":40},{"date":163,"type":40},"2023-06-15",{"date":165,"type":21},"2026-09-15",{"name":46,"class":47},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":59,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":100},"100525535","modified-widman-flap-vs-fibre-retention-osseous-resective-surgery-100525535","NCT06123000","Modified Widman Flap vs Fibre Retention Osseous Resective Surgery","Modified Widman Flap (MWF) vs Fibre Retention Osseous Resective Surgery (FibReORS): A Randomized, Controlled, Clinical Trial.","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Patients affected by periodontitis;\n* No systemic disease or pregnancy;\n* No systemic antibiotic therapy in 6 months preceding the enrollment;\n* Smoking ≤ 20 cigarettes\u002Fday;\n* Full-mouth plaque score (FMPS) and full- mouth bleeding score (FMBS) ≤ 15%;\n* Residual periodontal pocket ≥5 mm with bleeding on probing at posterior natural teeth;\n* Experimental pocket associated with a detectable infrabony defect ≤ 3mm at x-ray;\n* No history of periodontal surgery at the experimental site.\n\nExclusion Criteria:\n\n* Undetectable cemento-enamel junction (CEJ) at experimental teeth;\n* Severe furcation involvement (class II and III);\n* Abutment for prosthetic rehabilitation;\n* Periodontal Pockets associated with infrabony defect \\>3 mm;\n* Horizontal bone loss higher than 1\u002F3 of the root length at experimental teeth;\n* Severe tooth mobility at baseline (class 2 or 3).",{"count":175,"type":21},36,[61],"The treatment of periodontitis should be carried out in an incremental manner, first by achieving adequate patient's oral hygiene practices and risk factor control during the first step of therapy and then, during the second step of therapy, by professional elimination (reduction) of supra and subgingival biofilm and calculus.\n\nIf the endpoints of therapy (no periodontal pockets \\>4 mm with bleeding on probing, BoP, or deep pockets ≥5 mm) have not been achieved, the third step of therapy should be implemented.\n\nIn fact, residual pockets following step 1 and 2 of periodontal treatment are associated with increased risk of periodontal disease progression in the long-term as reported by Claffey \\& Egelberg in1995. Residual probing depth (PPD) ≥5 mm after active therapy is a risk factor for disease progression and tooth loss during supportive periodontal therapy (SPT), suggesting that additional treatment of residual pockets is strongly recommended.\n\nThe third step of treatment includes the following interventions: repeated subgingival instrumentation, access flap periodontal surgery, resective periodontal surgery, regenerative periodontal surgery.\n\nIn case of residual pockets associated with shallow-moderate infrabony defects at posterior teeth, where both regenerative therapy and non-surgical re-instrumentation are usually not indicated, access flap procedures (i.e., the Modified Widman Flap, MWF) and the Osseous Resective Surgery (ORS) are considered two of the most viable options.\n\nThe value of these surgical techniques has been tested over the years by different clinical trials, and the choice of a surgical approach still relies mainly on the decision-making process of the surgeon, since the long-term outcomes of the different periodontal surgical procedures are similar, as highlighted by a recent systematic review.\n\nNevertheless, one the main criticism that have been moved against ORS, lies on the fact that the side effects (i.e., gingival recessions) seem to be more severe for ORS surgery, when compared with MWF.\n\nIn the early 2000s, Carnevale proposed the Fibre Retention Osseous Resective Surgery (FibReORS), an approach that leads to a more conservative bone resection to eliminate infrabony defects and establish a positive bony architecture than the conventional ORS. Indeed, this one, based on the histological findings by Gargiulo et al. (1961), uses the level of the connective tissue attachment - rather than the bottom of the osseous defect - as the reference to apply the principles of ORS.\n\nTwo randomized clinical trials demonstrated that FibReORS is similarly effective as ORS for PPD reduction with less final gingival recessions (REC), clinical attachment loss (CAL) patient morbidity.\n\nNevertheless, no studies have ever directly compared FibreORS with MWF. Therefore, the aim of this randomized clinical trial (RCT) is to compare the efficacy of FibReORS versus MWF in the treatment of periodontal pockets associated with infrabony defects ≤3 mm at posterior natural teeth.\n\nObjectives\n\nThe experimental hypothesis is:\n\nFibReORS is superior to MWF in achieving PPD closure (PPD \\\u003C4 mm without BoP) at posterior teeth associated with shallow-moderate infrabony defects.",[179,180,181],"Periodontitis","Periodontal Pocket","Periodontal Attachment Loss","2025-04-07",{"date":184,"type":40},"2025-04-10",{"date":186,"type":40},"2024-10-21",{"date":188,"type":21},"2026-10-21",{"name":46,"class":47},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":198,"sex":17,"minAge":18,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":202,"conditions":203,"keywords":207,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":4},"100586161","eosinophil-subpopulations-in-eosinophilic-associated-diseases-100586161","NCT06911775","Eosinophil Subpopulations in Eosinophilic-associated Diseases","Exploring Inflammatory and Regulatory Eosinophil Subpopulations: the Path to Precision Medicine for the Treatment of Eosinophilic-associated Diseases","IREOS","Inclusion Criteria:\n\n\\- For inclusion in the study subjects should fulfill the following criteria based on local regulations:\n\nPatients with Asthma, or EGPA or HES:\n\n1. Age between 18 and 75 years at the time of signing the informed consent\n2. Patients with EA, EGPA or HES\n3. Provision of signed and dated written informed consent form prior to any mandatory study procedures, sampling and analysis.\n\nHealthy donors:\n\n1\\. Age between18 and 75 years healthy donors\n\nExclusion Criteria:\n\n* Subjects should not enter the study if any of the following exclusion criteria are fulfilled:\n\n  1. Presence of other chronic pulmonary diseases including COPD\n  2. Presence of other chronic immuno-mediated inflammatory diseases\n  3. Treatment with oral prednisone or equivalent \\> 7.5 mg\u002Fday\n  4. Treatment with long-acting depot corticosteroids in the last three months\n  5. Use of immunosuppressive medications (cyclosporine A; azathioprine; methotrexate; mycophenolate mofetil)\n  6. Receipt of live attenuated vaccines 30 days prior to the enrollment\n  7. Acute upper or lower respiratory infections within 30 days prior to the date informed consent is obtained or during the screening\u002Frun-in period.\n  8. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to, standard of care therapy\n  9. Subjects who are pregnant or breastfeeding\n  10. Current smoking\n  11. Any clinically significant abnormal findings in physical examination, vital signs, hematology, or clinical chemistry during screening period, which in the opinion of the investigator may put the patient at risk of his\u002Fher participation in the study, or may influence the results of the study, or the patient\\'s ability to complete entire duration of the study.\n  12. Concurrent enrolment in another interventional or post-authorization safety study.",true,"75 Years",{"count":201,"type":21},160,"This single-center, non-commercial study will involve 160 participants (80 with eosinophilic asthma (EA), 30 with eosinophilic granulomatosis with polyangiitis (EGPA), 25 with hypereosinophilic syndrome (HES), and 25 healthy donors) to investigate eosinophil subpopulations in these diseases. The study will run from Q4 2024 to Q4 2026.\n\nObjectives:\n\nPrimary: To verify two eosinophil subpopulations (iEos and rEos) in EGPA and HES and analyze the role of type 2 cytokines on their plasticity.\n\nSecondary: Compare iEos proportion between different eosinophilic diseases and correlate with disease severity.\n\nExploratory: Assess the effect of mepolizumab on eosinophil subpopulations in vitro.\n\nPopulation: Adults aged 18-75 with EA, EGPA, or HES, and healthy controls. EA patients must have \\>300 eosinophils\u002FmcL, EGPA requires asthma + eosinophilia + other specific features, and HES requires high eosinophil counts (\\>1500 cells\u002FmL).\n\nMethods: Data will be analyzed using Mann-Whitney U, ANOVA, and Spearman correlation tests, with results presented as mean ± SEM.\n\nThis study will help explore eosinophil behavior in eosinophilic diseases and evaluate mepolizumab's effects on these cells.",[204,205,206],"Eosinophilic Asthma","Eosinophilic Granulomatosis With Polyangiitis (EGPA)","Hypereosinophilic Syndrome (HES)",[208,209,210,211,212,213,214,215,216,217],"Eosinophils","EGPA","HES","EA","Eosinophilic asthma","Eosinophil subpopulations","Flowcytometry","Biomarker","Asthma severity","EGPA severity","2025-03-27",{"date":220,"type":40},"2025-04-04",{"date":222,"type":21},"2025-04",{"date":224,"type":21},"2026-12",{"name":46,"class":47},{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":59,"phases":236,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":100},"100584070","robotic-rehabilitation-vs-occupational-therapy-chronic-stroke-upper-limb-rehabilitation-100584070","NCT06884553","Robotic Rehabilitation Vs Occupational Therapy Chronic Stroke Upper Limb Rehabilitation","Effects of Robot-assistED Rehabilitation Versus OccupatIonal Therapy on the Functional Recovery of the Upper Limb in PatiEnts with Chronic STroke: a Randomized Controlled Trial","REDIRECT","Inclusion Criteria:\n\n1. First ischemic or hemorrhagic stroke occurring at least 6 months prior.\n2. Persistent motor deficit in the affected upper limb (Motricity Index between 18 and 77).\n3. Willingness to participate in the study, with the provision of informed consent.\n\nExclusion Criteria:\n\n1. Severe spastic hypertonia at the wrist and fingers (Modified Ashworth Scale equal to or greater than 3).\n2. Orthopedic, rheumatological, and\u002For peripheral nervous system disorders affecting the paretic upper limb.\n3. Neurodegenerative and neuromuscular disorders.\n4. Acute pathologies affecting other body systems.\n5. Severe cognitive, language, and behavioral disorders that significantly limit understanding and participation in the planned activities.",{"count":235,"type":21},72,[61],"The functional recovery of the upper limb represents a critical element in post-stroke rehabilitation; hemiplegic\u002Fhemiparetic patients who achieve optimal recovery are a minority, and incomplete recovery has relevant consequences both on functioning and on quality of life of those who survive a stroke. The project aims to assess the effects on the functional recovery, with manual dexterity as the primary outcome, of a treatment protocol using an innovative tool (Gloreha Sinfonia) that enables assisted execution of three-dimensional tasks combined with Serious Games for cognitive stimulation, targeting the functional recovery of the upper limb in patients with stroke outcomes at least 6 months after the acute event (chronic phase). Patients with residual dysfunction of the upper limb, at least 6 months after the stroke, will be randomly assigned to the Robotic Rehabilitation group (ROBOT), the Occupational Therapy group (OT), focused on the use of the upper limb in functional tasks (task-oriented training), or the control group (CT - prescription of a home exercise program). Patients in the ROBOT and OT groups will undergo a total treatment period of 5 weeks, with 3 sessions per week lasting 1 hour, for a total of 15 sessions\u002Fhours of treatment. Patients assigned to the CT group will undergo an initial functional assessment required for defining the exercise program. All patients will be evaluated at baseline (T0), at a 5-week interval (T1), and 6 months after the end of treatment (T2). Outcome indicators include measures of manual dexterity\u002Fupper limb performance, anxiety\u002Fdepression, cognitive abilities, and patient-perceived outcomes. The analysis of Surface Plasmon Resonance imaging (SPRi) of serum exosome content, detected at T0, T1, and T2, will be correlated with variations in functional measures to verify the hypothesis that induction of neuroplasticity underlies any observed changes. Short- and medium-term effects on functional, psychological outcomes, as well as indicators of neuroinflammation and neural regeneration from serum analysis using innovative SPRi, will be compared among the 3 groups.",[239],"Chronic Stroke",[241,242,243,244,245,246],"Robotic rehabilitation","occupational therapy","chronic stroke","upper limb impairment","biomarkers","manual dexterity","2025-03-13",{"date":249,"type":40},"2025-03-19",{"date":251,"type":40},"2023-09-19",{"date":253,"type":21},"2025-09-19",{"name":46,"class":47},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":100},"100562398","melcaya---novel-health-care-strategies-for-melanoma-in-children-adolescents-and-young-adults---work-package-3-wp3-100562398","NCT06602648","MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)","Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults. Histological, Computational, and Molecular Pathology for Improved Diagnosis. (Mol-Mel). Work Package 3 (WP3)","Mol-Mel","Inclusion Criteria:\n\n* adolescent and childhood patients (\\< 20 years) or young adults (\\< 30 years)\n* histologically confirmed diagnosis of melanoma or intermediate\u002Fambiguous melanocytic neoplasm (i.e., melanocytomas, SAMPUS, IAMPUS and MELTUMP according to WHO classification)\n\nExclusion criteria:\n\n* adult patients (\\> 30 years of age)\n* patients without histologically confirmed diagnosis of melanoma or intermediate\u002Fambiguous melanocytic neoplasm","30 Years",{"count":20,"type":21},"The aim of this study is to investigate a type of skin cancer, also known as melanoma, in children, adolescents, and young adults, who will be referred to as CAYA patients in this project. The need for this study arises because this disease, in CAYA patients, is still poorly understood due to its rarity in individuals under 30 years old. This often leads to difficulties in assessing its severity and, consequently, in deciding on the necessary treatments to ensure the patient\\'s recovery. The goal of this study is to examine melanoma in CAYA patients in order to gather the information needed to provide better diagnoses for affected patients and, as a result, select appropriate treatments to fight the disease and promote the patient\\'s full recovery. Additionally, the data collected will be used to create a Pan-European online platform that will allow doctors across the European Union to consult the obtained data and collaborate on particularly complex melanoma cases, always with the aim of ensuring the patient\\'s full recovery in the shortest possible time.",[267],"Melanoma of Skin",[269,270,271,272,273],"Melanoma","Pediatric","Childrens","Adolescents","Young adults","2024-09-17",{"date":276,"type":40},"2024-09-19",{"date":278,"type":40},"2024-04-17",{"date":280,"type":21},"2026-11",{"name":46,"class":47},{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":289,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":292,"studyType":23,"phases":4,"briefSummary":293,"conditions":294,"keywords":297,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":100},"100559460","european-registry-for-transperineal-laser-ablation-of-prostate-tpla-for-lower-urinary-tract-symptoms-100559460","NCT06564415","European Registry for Transperineal Laser Ablation of Prostate (TPLA) for Lower Urinary Tract Symptoms","European Registry for Transperineal Laser Ablation of Prostate (TPLA) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Obstruction (BPO)","Inclusion Criteria:\n\n* Age ≥18 years;\n* Prostate volume ≥ 30 mL;\n* Moderate-to-severe LUTS according to International Prostatic Symptoms Score (IPSS ≥8)\n* Consent to participate;\n\nExclusion Criteria:\n\n* Absence of consent;\n* Subsequent withdrawal of consent;\n* Diagnosis or suspicion of prostate cancer at multiparametric magnetic resonance\n* Documented bladder impaired contractility\n* Urethral stenosis\n* Previous prostate surgery","MALE",{"count":291,"type":21},2500,"5 Years","The goal of this observational study is to assess mid- and long-term effectiveness of Transperineal Laser Ablation of Prostate (TPLA) for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic obstruction measured by need and\u002For time until surgical retreatment.\n\nData regarding patient-reported outcomes measures (PROMs), flowmetry parameters and safety about consecutive patients undergoing TPLA will be collected in a dedicated platform.\n\nSecondary objectives of the study are:\n\n* To assess functional and safety outcomes in patients treated with transperineal laser ablation for LUTS due to benign prostatic obstruction;\n* To identify possible differences in characteristics of patients treated with transperineal laser ablation among the centers and possible relations between treatment application and outcomes, in order to explore the optimal indications and possible limitations of TPLA for LUTS.",[295,296],"Benign Prostatic Hyperplasia","Prostatic Diseases",[298,299,300,301,302],"TPLA","Transperineal Laser Ablation","LUTS","BPH","Benign Prostatic Obstruction","2024-08-18",{"date":305,"type":40},"2024-08-21",{"date":307,"type":40},"2024-01-11",{"date":309,"type":21},"2034-01",{"name":46,"class":47},{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":318,"targetDuration":320,"studyType":23,"phases":4,"briefSummary":321,"conditions":322,"keywords":328,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":100},"100431626","robotic-radical-cystectomy-outcomes-100431626","NCT04900558","Robotic Radical Cystectomy Outcomes","Impact of Robotic Surgery on Post-operative Outcomes of Patients Who Underwent Radical Cystectomy","Inclusion Criteria:\n\n* Age major or equal 18 years\n* Patients who will undergo radical cystectomy\n* Consent to participate\n\nExclusion Criteria:\n\n* Absence of willingness to participate\n* Further refusal to participate to the study",{"count":319,"type":21},500,"7 Years","Currently, in the treatment of bladder cancer the use of robotics has entered in clinical practice, therefor robotic radical cystectomy with or without reconstruction is offered to patients during counseling procedures, if deemed appropriate and possible. The aim of the study is therefore the long-term evaluation of the peri-post-operative, oncological and functional results of patients undergoing radical cystectomy, both with an open and robotic approach. This study will thus help to clarify the actual impact of robotic surgery",[323,324,325,326,327],"Bladder Cancer","Muscle-Invasive Bladder Carcinoma","Oncology","Recurrence","Surgery",[329,330,331,332,323,333],"Cystectomy","Radical Cystectomy","Ileal Conduit","Neobladder","Muscle Invasive Bladder Cancer","2021-05-19",{"date":336,"type":40},"2021-05-25",{"date":338,"type":40},"2021-04-29",{"date":340,"type":21},"2038-02-01",{"name":46,"class":47},{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":350,"enrollmentInfo":351,"targetDuration":352,"studyType":23,"phases":4,"briefSummary":353,"conditions":354,"keywords":360,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":100},"100387892","post-surgery-extracorporeal-life-support-100387892","NCT04330651","Post-Surgery Extracorporeal Life Support","Outcomes' Predictors in Post-Surgery Extracorporeal Life Support","PC-ECLS","Inclusion Criteria:\n\n* Patients underwent cardiac surgery\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years","80 Years",{"count":319,"type":21},"20 Years","Extracorporeal Life Support (ECLS) may provide pulmonary and circulatory support for patients with acute heart failure refractory to conventional medical therapy. However, indications and effectiveness of ECLS engagement post-surgery remains a concern. The investigators sought to analyze indications, modality and outcomes of PS-ECLS, to identify predictors of early and midterm survival after PS-ECLS. The investigators have recorded prospectively, and analysed data of 209 consecutive PS-ECLS patients between January 2004 and December 2018. Demographic and clinical data before, during and after PS-ECLS were collected and their influence on hospital mortality and outcomes (early and midterm) will analyse. Multivariate analysis of pre PS-ECLS implantation factors (as age, female sex , insulin-dependent diabetes, pulmonary hypertension, STS, type of surgical procedure data, pre-ECLS blood lactate level) will be made for identify prognostic risk factors of in-hospital mortality. Overall survival will be analysed, at 6 months,1-year and 5-years, respectively and the factors influencing mild\u002Fterm outcome will be investigated.",[355,356,357,358,359],"Cardiogenic Shock","Extracorporeal Life Support","Extracorporeal Membrane Oxygenation Complication","Post Cardiac Arrest Syndrome","Post-cardiac Surgery",[361,362,363,364,365,366],"extracorporeal life support","ecls","ecmo","outocome","prognostic factors","extracorporeal membrane oxygenation","2021-04-27",{"date":369,"type":40},"2021-04-28",{"date":371,"type":4},"2004-01",{"date":373,"type":21},"2029-01-31",{"name":46,"class":47},""]